Bei Akademie registrieren
Novartis, CH0012005267

Novartis stock gains 1.90% since previous BioArctic report

Published on 11/05/2026 at 17:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock has extended its move since the previous report. Investors continue to watch the drugmaker's research pipeline and partnership decisions.

What changed for Novartis investors

  • The stock has moved materially since the previous Novartis report.
  • The earlier report focused on the end of a BioArctic research program.
  • The next investor focus remains the company's pipeline and future clinical progress.
Novartis, CH0012005267, Illustration mit AI erstellt.
Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis stock has extended its move since the previous report on the end of a research program with BioArctic. The latest quote gives investors a fresh reference point after the earlier update focused on the discontinued collaboration.

Stock advances since previous report

Novartis stock traded at 146.77 euros on Lang & Schwarz at 17:38 CET on Thursday, November 5, 2026. That was 1.90 percent above the 144.03-euro Lang & Schwarz quote recorded in the previous report on Wednesday, November 4, 2026 at 11:43 CET. This is a separate comparison with the previous report's quote, not the daily Xetra comparison.

The move adds a market update to the company's recent research news. The previous report said Novartis had ended an agreement with BioArctic covering a potential neurological medicine that combined BioArctic's BrainTransporter technology with an undisclosed Novartis antibody.

Pipeline decisions remain relevant

BioArctic said the decision concerned the specific Novartis program rather than the BrainTransporter technology. The earlier report also stated that BioArctic would retain the 30 million US dollar upfront payment and recognize the unrecognized portion as 2026 revenue.

For Novartis investors, the termination highlights the selective nature of the drugmaker's research portfolio. The stock comparison shows a notable change since the prior report, while the program decision itself remains an early-stage pipeline matter rather than a clinical readout.

For a live market reference, see the real-time quote of Novartis stock.

The broader Swiss market setting remains relevant for pharmaceutical shares; see the SMI market topic.

More news and analyses on Novartis stock are available in the Novartis stock topic.

Novartis AG

  • Company: Novartis AG
  • ISIN: CH0012005267
  • WKN: 904278
  • Trading venue: Lang & Schwarz
  • Quote: 146.77 euros on November 5, 2026 at 17:38 CET
  • Change since previous report: 1.90 percent from 144.03 euros on November 4, 2026
Disclaimer...
en | CH0012005267 | NOVARTIS | boerse | 70465465 |